A Study of the Prevention of Alloimmunisation using Leukocyte-Depleted Red Cell and Platelet Donations

ISRCTN ISRCTN43344383
DOI https://doi.org/10.1186/ISRCTN43344383
Secondary identifying numbers LK/FIL
Submission date
19/08/2002
Registration date
19/08/2002
Last edited
11/01/2019
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Cancer
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr - -
Scientific

UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
NW1 2DA
United Kingdom

Study information

Study designRandomised controlled trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Not specified
Study typeNot Specified
Scientific titleA Study of the Prevention of Alloimmunisation using Leukocyte-Depleted Red Cell and Platelet Donations
Study objectivesNot provided at time of registration
Ethics approval(s)Not provided at time of registration
Health condition(s) or problem(s) studiedLeukaemia (acute), Leukaemia (chronic)
Intervention1. Arm A: Patients receive standard non-filtered, non-leukocyte-depleted blood products
2. Arm B: Patients receive Pall filtered blood or platelet donations
Intervention typeDrug
Pharmaceutical study type(s)
PhaseNot Specified
Drug / device / biological / vaccine name(s)Leukocyte-Depleted Red Cell and Platelet Donations
Primary outcome measureNot provided at time of registration
Secondary outcome measuresNot provided at time of registration
Overall study start date01/01/1990
Completion date01/04/1992

Eligibility

Participant type(s)Patient
Age groupNot Specified
SexNot Specified
Target number of participantsNot provided at time of registration
Key inclusion criteria1. Patients with acute leukaemia, chronic myeloid leukaemia, severe aplastic anaemia or high grade lymphoma
2. Patients already known to have Human Leukocyte Antigens (HLA) antibodies or recurrent febrile transfusion reactions are ineligible
3. Any age
4. Fit to undergo the treatments as defined in protocol
Key exclusion criteriaNot provided at time of registration
Date of first enrolment01/01/1990
Date of final enrolment01/04/1992

Locations

Countries of recruitment

  • England
  • United Kingdom

Study participating centre

UKCCCR Register Co-ordinator
London
NW1 2DA
United Kingdom

Sponsor information

Pall Biomedical Ltd (UK)
Industry

Europa House
Havant Street
Portsmouth
PO1 3PD
United Kingdom

Website http://www.pall.com/
ROR logo "ROR" https://ror.org/04hw9y579

Funders

Funder type

Industry

Pall Biomedical Ltd (UK)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Editorial Notes

11/01/2019: No publications found. All search options exhausted.